A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients With HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab With Chemotherapy Plus Trastuzumab Plus Bevacizumab
收藏DataCite Commons2025-06-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008303/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in
patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.
提供机构：
Vivli
创建时间：
2022-07-22
